Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1965 1
1966 2
1973 2
1974 2
1975 7
1976 4
1977 12
1978 1
1979 6
1980 7
1981 10
1982 4
1983 3
1984 1
1985 7
1986 5
1987 1
1988 3
1989 3
1990 4
1991 4
1992 4
1993 1
1995 6
1996 2
1997 3
1998 4
1999 6
2000 4
2001 2
2002 4
2003 8
2004 7
2005 7
2006 5
2007 14
2008 16
2009 11
2010 10
2011 12
2012 20
2013 21
2014 19
2015 28
2016 20
2017 16
2018 12
2019 19
2020 30
2021 24
2022 35
2023 32
2024 28
2025 38
2026 43

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

536 results

Results by year

Filters applied: . Clear all
Page 1
Guideline for the management of myasthenic syndromes.
Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K, Hoffmann S, Hoffmann HS, Jander S, Keller C, Marx A, Melms A, Melzer N, Müller-Felber W, Pawlitzki M, Rückert JC, Schneider-Gold C, Schoser B, Schreiner B, Schroeter M, Schubert B, Sieb JP, Zimprich F, Meisel A. Wiendl H, et al. Among authors: meisel a. Ther Adv Neurol Disord. 2023 Dec 26;16:17562864231213240. doi: 10.1177/17562864231213240. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 38152089 Free PMC article. Review.
Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, Enayetallah A, Beasley KN, Rampal N, Howard JF. Vu T, et al. Among authors: meisel a. NEJM Evid. 2022 May;1(5):EVIDoa2100066. doi: 10.1056/EVIDoa2100066. Epub 2022 Apr 26. NEJM Evid. 2022. PMID: 38319212 Clinical Trial.
C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis.
Huntemann N, Gerischer L, Herdick M, Nelke C, Stascheit F, Hoffmann S, Öztürk M, Schroeter CB, Lehnerer S, Stein M, Schubert C, Schneider-Gold C, Pfeuffer S, Krämer HH, Konen FF, Skripuletz T, Pawlitzki M, Glaubitz S, Zschüntzsch J, Scherwietes V, Totzeck A, Hagenacker T, Meuth SG, Meisel A, Ruck T. Huntemann N, et al. Among authors: meisel a. J Neurol Neurosurg Psychiatry. 2025 Mar 24;96(4):310-321. doi: 10.1136/jnnp-2024-334404. J Neurol Neurosurg Psychiatry. 2025. PMID: 39798960 Free PMC article.
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
Meisel A, Annane D, Vu T, Mantegazza R, Katsuno M, Aguzzi R, Frick G, Gault L, Howard JF Jr; CHAMPION MG Study Group. Meisel A, et al. J Neurol. 2023 Aug;270(8):3862-3875. doi: 10.1007/s00415-023-11699-x. Epub 2023 Apr 27. J Neurol. 2023. PMID: 37103755 Free PMC article. Clinical Trial.
Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension.
Vu TH, Mantegazza R, Annane D, Katsuno M, Meisel A, Nicolle MW, Bril V, Aguzzi R, Frick G, Howard JF Jr; CHAMPION MG Study Group. Vu TH, et al. Among authors: meisel a. Eur J Neurol. 2025 Apr;32(4):e70158. doi: 10.1111/ene.70158. Eur J Neurol. 2025. PMID: 40241307 Free PMC article. Clinical Trial.
536 results